US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elicio Therapeutics

9.89

+0.08000.82%

Post-market: 9.890.00000.00%17:48 EDT

Volume:35.16K

Turnover:346.75K

Market Cap:158.07M

PE:-2.48

High:10.15

Open:10.15

Low:9.50

Close:9.81

Loading ...

Overview Company News Filings

BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple

BUZZ-Elicio signals delay in mid-stage cancer vaccine study; shares slump

Elicio Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into Q4 2025

Press Release: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Elicio Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Elicio Therapeutics Names Preetam Shah CFO

MT Newswires Live

Elicio Therapeutics Hires CFO From Cidara Therapeutics

Elicio Therapeutics Appoints Preetam Shah, Ph.d., MBA, as Chief Strategy and Financial Officer

THOMSON REUTERS

Press Release: Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

With 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stake

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS

Elicio Therapeutics Inc - Offering Closing Expected on or About January 30, 2025

THOMSON REUTERS

Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Elicio Therapeutics Advances with New Clinical Updates

JonesTrading Reaffirms Their Buy Rating on Elicio Therapeutics (ELTX)

Elicio reaches alignment with FDA on ELI-002 registrational strategy

Elicio Therapeutics: Phase 2 Randomized Study of Eli-002 Fully Enrolled, With Formal Interim Analysis of Disease-Free Survival Expected in H1 2025

THOMSON REUTERS

Elicio Therapeutics Reaches Alignment With FDA on Eli-002 Registrational Strategy

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ELTX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ELTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":9.89,"timestamp":1753473600000,"preClose":9.81,"halted":0,"volume":35162,"hourTrading":{"tag":"盘后","latestPrice":9.89,"preClose":9.89,"latestTime":"17:48 EDT","volume":21,"amount":209.89,"timestamp":1753480126126},"delay":0,"floatShares":10299118,"shares":15982521,"eps":-3.983791,"marketStatus":"Market Closed","change":0.08,"latestTime":"07-25 16:00:00 EDT","open":10.15,"high":10.15,"low":9.5,"amount":346751.188184,"amplitude":0.066259,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.983791,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":9.81,"postHourTrading":{"tag":"盘后","latestPrice":9.89,"preClose":9.89,"latestTime":"17:48 EDT","volume":21,"amount":209.89,"timestamp":1753480126126},"volumeRatio":0.7837254734119443,"impliedVol":0.6855,"impliedVolPercentile":0.5942},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ELTX\",,,,,undefined,":{"symbol":"ELTX","floatShares":10299118,"roa":"-108.03%","roe":"-744.59%","lyrEps":-4.25289,"volumeRatio":0.7837254734119443,"shares":15982521,"dividePrice":0,"high":10.15,"amplitude":0.066259,"preClose":9.81,"low":9.5,"week52Low":3.7,"pbRate":"17.75","week52High":10.39,"institutionHeld":0,"latestPrice":9.89,"eps":-3.983791,"divideRate":0,"volume":35162,"delay":0,"ttmEps":-3.983791,"open":10.15,"prevYearClose":5.1,"prevWeekClose":9.34,"prevMonthClose":7.72,"prevQuarterClose":7.72,"fiveDayClose":9.34,"twentyDayClose":7.9,"sixtyDayClose":4.81},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ELTX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524047975","title":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=2524047975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524047975?lang=en_us&edition=fundamental","pubTime":"2025-04-01 02:29","pubTimestamp":1743445744,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, AppleMarch 31 (Reuters) - The S&P 500 and the Nasdaq declined on Monday, with technology stocks among the largest fallers, as inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE16T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALSN","AIG","BK4017","PINS","LPLA","LU0820561818.USD","ALNY","NVAX","TSHA","ELTX","NOVA","RKT","LU0316494557.USD","LU1674673428.USD","SG9999015358.SGD","LYV","LU1674673691.USD","GATE","LITB","BLUE","LU2552382215.SGD","GT","LU0061475181.USD","TSYW.SI","BK4532","GSK.UK","PL","FBK","FLG","SRPT","SG9999014567.USD","NEM","GLPI","LU1145028129.USD","PG","BK4539","IIPR","EBS","ENZ","SLDB","IDYA","HMST","SSBK","VBTX","COOP"],"gpt_icon":1},{"id":"2524978939","title":"BUZZ-Elicio signals delay in mid-stage cancer vaccine study; shares slump","url":"https://stock-news.laohu8.com/highlight/detail?id=2524978939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524978939?lang=en_us&edition=fundamental","pubTime":"2025-04-01 01:25","pubTimestamp":1743441957,"startTime":"0","endTime":"0","summary":"BUZZ-Elicio signals delay in mid-stage cancer vaccine study; shares slump** Biotech firm Elicio Therapeutics' ELTX.O shares fall 14% to an over 2-month low of $6.71  ** ELTX now expects mid-stage study data of its lead experimental vaccine, ELI-002, in Q3 2025 vs. previous expectation of H1 2025** Co is testing vaccine against certain types of solid tumors that are caused by mutations in the KRAS gene, which are common in pancreatic, colorectal, and non-small cell lung cancers** ELTX's net loss also widens in 2024 compared with 2023** As of last close, ELTX has risen 2.5% in the past 12 months","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ELTX"],"gpt_icon":0},{"id":"2523094221","title":"Elicio Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2523094221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523094221?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:31","pubTimestamp":1743427876,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryElicio Therapeutics Inc ELTX.OQ reported a quarterly adjusted loss of $1.02 per share for the quarter ended ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL5N3QE0Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2523103029","title":"Elicio Therapeutics FY 2024 GAAP EPS $(4.25) Misses $(3.56) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $17.6M. Including $10M In Gross Proceeds From January 2025 Registered Direct Offering, The Company Expects Cash Runway Into Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2523103029","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523103029?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:17","pubTimestamp":1743419828,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(4.25) per share which missed the analyst consensus estimate of $(3.56) by 19.38 percent. This is a 38.94 percent increase over losses of $(6.96) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44558596/elicio-therapeutics-fy-2024-gaap-eps-4-25-misses-3-56-estimate-as-of-december-31-2024-cash-and-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2523912207","title":"Press Release: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912207","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912207?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival  event-driven interim analysis expected in Q3 2025. Aligned with U.S. Food and Drug Administration  on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis. Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis. BOSTON, March 31, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2024 and provided recent corporate and clinical updates.-- In March 2025, Elicio appointed Preetam Shah, Ph.D., MBA, as Chief. -- In January 2025, Elicio strengthened its cash position with a $10.0. a registrational strategy for ELI-002 in post-resection (adjuvant. Elicio aligned with the FDA on key elements of a planned Phase 3 study","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2522078161","title":"Elicio Therapeutics Inc  expected to post a loss of 87 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522078161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522078161?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:32","pubTimestamp":1742905973,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics Inc  expected to post a loss of87cents a share - Earnings Preview Elicio Therapeutics Inc ELTX.OQ ELTX.O is expected to show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nL5N3Q80Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX"],"gpt_icon":0},{"id":"2521742428","title":"Elicio Therapeutics Names Preetam Shah CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2521742428","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521742428?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:57","pubTimestamp":1742817478,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) said Monday that it has named Preetam Shah as its chief financial officer and chief strategy officer, starting immediately.Shah previously was CFO and chief business officer of biotech firm Cidara Therapeutics (CDTX).","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ELTX","BK4007","CDTX"],"gpt_icon":0},{"id":"2521974283","title":"Elicio Therapeutics Hires CFO From Cidara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2521974283","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521974283?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:46","pubTimestamp":1742816760,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics has hired the former chief financial officer of Cidara Therapeutics to lead its strategy and finances.The Boston-based Elicio said Monday that Preetam Shah has been appointed chief strategy and financial officer.Shah will also serve as the biotechnology company's principal financial officer and principal accounting officer.He most recently served as the chief financial officer and chief business officer of fellow biotech Cidara. Before that, Shah was the CFO for Brainstorm Cell Therapeutics and has held roles at Barclays Capital and Canaccord Genuity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4139","CDTX"],"gpt_icon":0},{"id":"2521746826","title":"Elicio Therapeutics Appoints Preetam Shah, Ph.d., MBA, as Chief Strategy and Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746826?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:02","pubTimestamp":1742814165,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nFWN3Q715W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2521745616","title":"Press Release: Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521745616","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521745616?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:00","pubTimestamp":1742814000,"startTime":"0","endTime":"0","summary":"BOSTON, March 24, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and in other senior leadership roles at multiple publicly traded biotechnology companies.\"We are pleased to welcome Preetam to Elicio's executive team,\" said Robert Connelly, Ph.D., President and Chief Executive Officer of Elicio. \"He joins us during an exciting time. We remain encouraged by the potential of ELI-002 and the broad applicability of the Amphiphile platform, and I am confident that Preetam's extensive experience in corporate finance, strategy, and business development will be a tremendous asset to our Company.\"","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2519803924","title":"With 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2519803924","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519803924?lang=en_us&edition=fundamental","pubTime":"2025-03-14 18:51","pubTimestamp":1741949494,"startTime":"0","endTime":"0","summary":"Significant insider control over Elicio Therapeutics implies vested interests in company growth. The largest shareholder of the company is Yekaterina Chudnovsky with a 50% stake. Past performance of a company along with ownership data serve to give a strong idea about prospects for a business. If you want to know who really controls Elicio Therapeutics, Inc. , then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 36% to be precise, is individual insiders. Put another way, the group faces the maximum upside potential .So, insiders of Elicio Therapeutics have a lot at stake and every decision they make on the company’s future is important to them from a financial point of view.Let's delve deeper into each type of owner of Elicio Therapeutics, beginning with the chart below.The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/36-ownership-elicio-therapeutics-inc-105134606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","IE00B64PRP62.GBP","BK4585","SQQQ","BK4112","NVIW.SI",".IXIC","USJW.SI","NQmain","IE00B3QW5Z07.USD","IE00BKPKM429.USD","MNQmain","TSYW.SI","ELTX","BK4588","NDAQ","BK4007","LU2210149790.SGD","LU2095319765.USD","QLD","PSQ","IE00BGHQF748.EUR","TQQQ","QID","BK4139","LU2210150020.SGD"],"gpt_icon":1},{"id":"2517319372","title":"Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517319372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517319372?lang=en_us&edition=fundamental","pubTime":"2025-03-07 01:20","pubTimestamp":1741281636,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fate Therapeutics (FATE – Research Report), ALX Onco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4080","FATE","BK4139","BK4231","ALX","HCSG","ELTX","ALXO","BK4137"],"gpt_icon":0},{"id":"2507279640","title":"Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2507279640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507279640?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA4CZBSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"2507164073","title":"Elicio Therapeutics Inc - Offering Closing Expected on or About January 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507164073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507164073?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250130:nTUA4CZBSP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2507400876","title":"Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2507400876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507400876?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242000,"startTime":"0","endTime":"0","summary":"BOSTON, Jan. 30, 2025  -- Elicio Therapeutics, Inc. , a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered into definitive securities purchase agreements with institutional investors for the purchase of an aggregate of 1,261,830 shares of its common stock and accompanying warrants to purchase up to an aggregate of 1,261,830 shares of its common stock, at a purchase price of $7.925 per share and accompanying warrant in a registered direct offering  priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $7.80 per share, will be exercisable immediately upon issuance, and will expire five years from the initial exercise date. The closing of the Offering is expected to occur on or about January 30, 2025, subject to the satisfaction of customary closing conditions.The aggregate gross proceeds to the Company from the Offering are expected to be approximately $10.0 mi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elicio-therapeutics-announces-10-0-130000704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","BK4139","SQQQ","NDAQ","LU2210150020.SGD","BK4112","TQQQ","PSQ","ELTX","MNQmain","BK4007","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","TSYW.SI",".IXIC","QLD","USAW.SI","USJW.SI","BK4585","NQmain","IE00B3QW5Z07.USD","BK4588","NVIW.SI","QID","LU2095319765.USD"],"gpt_icon":1},{"id":"2505024798","title":"Elicio Therapeutics Advances with New Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2505024798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505024798?lang=en_us&edition=fundamental","pubTime":"2025-01-24 06:01","pubTimestamp":1737669716,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics ( ($ELTX) ) has issued an announcement. On January 23, 2025, Elicio Therapeutics announced the addition of a corporate presenta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/elicio-therapeutics-advances-with-new-clinical-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/elicio-therapeutics-advances-with-new-clinical-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2505740777","title":"JonesTrading Reaffirms Their Buy Rating on Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2505740777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505740777?lang=en_us&edition=fundamental","pubTime":"2025-01-23 02:45","pubTimestamp":1737571510,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Elicio Therapeutics (ELTX – Research Report). The company’s sha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-reaffirms-their-buy-rating-on-elicio-therapeutics-eltx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX"],"gpt_icon":0},{"id":"2505741209","title":"Elicio reaches alignment with FDA on ELI-002 registrational strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2505741209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505741209?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:41","pubTimestamp":1737549665,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics (ELTX) announced that it has received supportive feedback in an End of Phase 1 Type B meeting with the U.S. Food and Drug Admin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/elicio-reaches-alignment-with-fda-on-eli-002-registrational-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/elicio-reaches-alignment-with-fda-on-eli-002-registrational-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","ELTX"],"gpt_icon":0},{"id":"2505491067","title":"Elicio Therapeutics: Phase 2 Randomized Study of Eli-002 Fully Enrolled, With Formal Interim Analysis of Disease-Free Survival Expected in H1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505491067","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505491067?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:30","pubTimestamp":1737549004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OI0PI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ELTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2505474910","title":"Elicio Therapeutics Reaches Alignment With FDA on Eli-002 Registrational Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2505474910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505474910?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:30","pubTimestamp":1737549004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nFWN3OI0PI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","ELTX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ELTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"ELTX","fiscalQuarterEnding":"2025/03","expectedEps":-0.67,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-0.87},{"market":"US","date":"2025-03-31","symbol":"ELTX","fiscalQuarterEnding":"2024/12","expectedEps":-0.94,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.02},{"market":"US","date":"2024-11-13","symbol":"ELTX","fiscalQuarterEnding":"2024/09","expectedEps":-0.81,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-1.39},{"market":"US","date":"2024-08-13","symbol":"ELTX","fiscalQuarterEnding":"2024/06","expectedEps":-0.96,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2024-05-15","symbol":"ELTX","fiscalQuarterEnding":"2024/03","expectedEps":-1.09,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":-1.15}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ELTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ELTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ELTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ELTX","date":"2025-07-25","current":-3.057499,"percent":0.05123,"low":-9.235249,"twenty":-2.600059,"median":-1.764061,"eighty":-1.263206,"high":-0.963611,"avg":-1.995435,"sd":0.981085,"marketCap":156788531},"quantilePoints":[{"date":"2023-06-09","current":-9.235249,"twenty":-9.235249,"median":-9.19865,"eighty":-8.861936,"marketCap":260505032},{"date":"2023-06-16","current":-4.797096,"twenty":-9.19133,"median":-5.471097,"eighty":-5.286091,"marketCap":135315000},{"date":"2023-06-23","current":-3.669177,"twenty":-9.011993,"median":-5.35246,"eighty":-4.343178,"marketCap":103499000},{"date":"2023-06-30","current":-3.232452,"twenty":-8.711878,"median":-5.281964,"eighty":-3.931212,"marketCap":91180000},{"date":"2023-07-07","current":-3.782657,"twenty":-7.82363,"median":-4.797096,"eighty":-3.594899,"marketCap":106700000},{"date":"2023-07-14","current":-3.799851,"twenty":-5.457342,"median":-4.009616,"eighty":-3.669177,"marketCap":107185000},{"date":"2023-07-21","current":-3.868626,"twenty":-5.416077,"median":-3.868626,"eighty":-3.616907,"marketCap":109125000},{"date":"2023-07-28","current":-3.026831,"twenty":-5.342487,"median":-3.782657,"eighty":-3.314983,"marketCap":85379914},{"date":"2023-08-04","current":-2.958445,"twenty":-5.286091,"median":-3.758585,"eighty":-2.99472,"marketCap":83450898},{"date":"2023-08-11","current":-2.973312,"twenty":-5.075638,"median":-3.643386,"eighty":-2.969744,"marketCap":83870250},{"date":"2023-08-18","current":-2.842099,"twenty":-4.570137,"median":-3.57633,"eighty":-2.953093,"marketCap":83656289},{"date":"2023-08-25","current":-2.726636,"twenty":-4.18018,"median":-3.222136,"eighty":-2.868421,"marketCap":79553028},{"date":"2023-09-01","current":-2.370739,"twenty":-4.067388,"median":-3.000071,"eighty":-2.849368,"marketCap":69169264},{"date":"2023-09-07","current":-2.433882,"twenty":-3.951844,"median":-2.973312,"eighty":-2.844375,"marketCap":71011545},{"date":"2023-09-15","current":-2.413791,"twenty":-3.886508,"median":-2.973312,"eighty":-2.761879,"marketCap":70425365},{"date":"2023-09-22","current":-2.293245,"twenty":-3.841116,"median":-2.967365,"eighty":-2.647421,"marketCap":66908283},{"date":"2023-09-29","current":-2.413791,"twenty":-3.792973,"median":-2.953985,"eighty":-2.537207,"marketCap":70425365},{"date":"2023-10-04","current":-2.276024,"twenty":-3.782657,"median":-2.940605,"eighty":-2.474064,"marketCap":66405843},{"date":"2023-10-10","current":-2.098075,"twenty":-3.781281,"median":-2.875192,"eighty":-2.428715,"marketCap":61213961},{"date":"2023-10-19","current":-2.009101,"twenty":-3.779218,"median":-2.868708,"eighty":-2.413791,"marketCap":58618021},{"date":"2023-10-27","current":-1.922996,"twenty":-3.775091,"median":-2.867273,"eighty":-2.413791,"marketCap":56105820},{"date":"2023-11-03","current":-1.871334,"twenty":-3.740703,"median":-2.849368,"eighty":-2.290949,"marketCap":54598499},{"date":"2023-11-10","current":-1.690515,"twenty":-3.669177,"median":-2.844944,"eighty":-2.243878,"marketCap":49322877},{"date":"2023-11-17","current":-1.533738,"twenty":-3.658861,"median":-2.768921,"eighty":-2.084298,"marketCap":50453368},{"date":"2023-11-24","current":-1.527374,"twenty":-3.617595,"median":-2.739552,"eighty":-1.974659,"marketCap":50244018},{"date":"2023-12-01","current":-1.565558,"twenty":-3.614157,"median":-2.617571,"eighty":-1.90147,"marketCap":51500118},{"date":"2023-12-08","current":-1.48919,"twenty":-3.583895,"median":-2.583129,"eighty":-1.87076,"marketCap":48987917},{"date":"2023-12-15","current":-1.540102,"twenty":-3.452534,"median":-2.531467,"eighty":-1.708711,"marketCap":50662718},{"date":"2023-12-22","current":-1.476462,"twenty":-3.314983,"median":-2.474064,"eighty":-1.60527,"marketCap":48569217},{"date":"2023-12-29","current":-2.102685,"twenty":-3.232452,"median":-2.429577,"eighty":-1.641927,"marketCap":69169264},{"date":"2024-01-05","current":-2.03949,"twenty":-3.220072,"median":-2.413791,"eighty":-1.611379,"marketCap":67090423},{"date":"2024-01-12","current":-1.576818,"twenty":-3.100826,"median":-2.392265,"eighty":-1.585578,"marketCap":51870515},{"date":"2024-01-19","current":-1.427896,"twenty":-3.005423,"median":-2.30616,"eighty":-1.564031,"marketCap":46971633},{"date":"2024-01-26","current":-1.124213,"twenty":-2.973312,"median":-2.283466,"eighty":-1.540772,"marketCap":36981756},{"date":"2024-02-02","current":-1.314015,"twenty":-2.973312,"median":-2.260238,"eighty":-1.528392,"marketCap":43225429},{"date":"2024-02-09","current":-1.226414,"twenty":-2.973312,"median":-2.227231,"eighty":-1.508027,"marketCap":40343734},{"date":"2024-02-16","current":-1.220574,"twenty":-2.970933,"median":-2.10038,"eighty":-1.496317,"marketCap":40151621},{"date":"2024-02-23","current":-1.170933,"twenty":-2.967365,"median":-2.077039,"eighty":-1.484607,"marketCap":38518660},{"date":"2024-03-01","current":-1.185534,"twenty":-2.965581,"median":-2.037802,"eighty":-1.427936,"marketCap":38998943},{"date":"2024-03-08","current":-1.305255,"twenty":-2.958445,"median":-1.951697,"eighty":-1.350807,"marketCap":42937259},{"date":"2024-03-15","current":-1.530098,"twenty":-2.956661,"median":-1.917256,"eighty":-1.360152,"marketCap":50333611},{"date":"2024-03-22","current":-1.927222,"twenty":-2.947741,"median":-1.909363,"eighty":-1.380707,"marketCap":63397296},{"date":"2024-03-28","current":-2.178345,"twenty":-2.940605,"median":-1.925109,"eighty":-1.425549,"marketCap":71658156},{"date":"2024-04-05","current":-2.18389,"twenty":-2.875192,"median":-1.928736,"eighty":-1.427896,"marketCap":76862025},{"date":"2024-04-12","current":-2.872164,"twenty":-2.872164,"median":-2.000282,"eighty":-1.428095,"marketCap":101085828},{"date":"2024-04-19","current":-2.390082,"twenty":-2.870144,"median":-2.037802,"eighty":-1.436656,"marketCap":84118945},{"date":"2024-04-26","current":-2.64274,"twenty":-2.867273,"median":-2.070475,"eighty":-1.460017,"marketCap":93011227},{"date":"2024-05-03","current":-2.613699,"twenty":-2.860548,"median":-2.080854,"eighty":-1.476462,"marketCap":91989126},{"date":"2024-05-10","current":-2.758904,"twenty":-2.852923,"median":-2.121507,"eighty":-1.483377,"marketCap":97099633},{"date":"2024-05-17","current":-2.458726,"twenty":-2.860548,"median":-2.154849,"eighty":-1.484098,"marketCap":95873111},{"date":"2024-05-24","current":-2.3198,"twenty":-2.852923,"median":-2.20556,"eighty":-1.486644,"marketCap":90455973},{"date":"2024-05-31","current":-1.968554,"twenty":-2.850079,"median":-2.181118,"eighty":-1.488681,"marketCap":76759815},{"date":"2024-06-07","current":-2.125179,"twenty":-2.849368,"median":-2.152608,"eighty":-1.489212,"marketCap":82867106},{"date":"2024-06-14","current":-2.233016,"twenty":-2.846714,"median":-2.152608,"eighty":-1.492255,"marketCap":87071996},{"date":"2024-06-21","current":-1.741174,"twenty":-2.844944,"median":-2.140329,"eighty":-1.496317,"marketCap":67893594},{"date":"2024-06-28","current":-1.812189,"twenty":-2.844944,"median":-2.140329,"eighty":-1.498354,"marketCap":70662668},{"date":"2024-07-05","current":-0.967903,"twenty":-2.843237,"median":-2.110101,"eighty":-1.488172,"marketCap":37741454},{"date":"2024-07-12","current":-1.249432,"twenty":-2.834001,"median":-2.100781,"eighty":-1.469884,"marketCap":48719089},{"date":"2024-07-15","current":-1.260464,"twenty":-2.831302,"median":-2.098877,"eighty":-1.455345,"marketCap":49149280},{"date":"2024-08-02","current":-1.401267,"twenty":-2.828603,"median":-2.098877,"eighty":-1.436656,"marketCap":54639616},{"date":"2024-08-09","current":-1.290931,"twenty":-2.802466,"median":-2.080854,"eighty":-1.401267,"marketCap":50337284},{"date":"2024-08-16","current":-1.201045,"twenty":-2.796658,"median":-2.072003,"eighty":-1.349055,"marketCap":46438413},{"date":"2024-08-23","current":-1.241178,"twenty":-2.769689,"median":-2.062918,"eighty":-1.296495,"marketCap":47990130},{"date":"2024-08-30","current":-1.113164,"twenty":-2.768153,"median":-2.038646,"eighty":-1.281895,"marketCap":43040476},{"date":"2024-09-06","current":-1.110381,"twenty":-2.760754,"median":-2.011962,"eighty":-1.261256,"marketCap":42932874},{"date":"2024-09-13","current":-1.132616,"twenty":-2.753755,"median":-1.991463,"eighty":-1.24953,"marketCap":43792608},{"date":"2024-09-20","current":-1.430415,"twenty":-2.736707,"median":-1.971607,"eighty":-1.23844,"marketCap":55307011},{"date":"2024-09-27","current":-1.355277,"twenty":-2.727862,"median":-1.927222,"eighty":-1.247781,"marketCap":52401779},{"date":"2024-10-04","current":-1.35806,"twenty":-2.717602,"median":-1.920126,"eighty":-1.24953,"marketCap":52509380},{"date":"2024-10-11","current":-1.333014,"twenty":-2.703726,"median":-1.89225,"eighty":-1.251663,"marketCap":51540970},{"date":"2024-10-18","current":-1.327448,"twenty":-2.69392,"median":-1.871334,"eighty":-1.251663,"marketCap":51325767},{"date":"2024-10-25","current":-1.330231,"twenty":-2.68748,"median":-1.868821,"eighty":-1.256738,"marketCap":51433368},{"date":"2024-10-31","current":-1.15769,"twenty":-2.682816,"median":-1.860061,"eighty":-1.249543,"marketCap":44762095},{"date":"2024-11-08","current":-1.282921,"twenty":-2.678751,"median":-1.809791,"eighty":-1.251136,"marketCap":49604148},{"date":"2024-11-15","current":-1.251898,"twenty":-2.674104,"median":-1.720841,"eighty":-1.252073,"marketCap":58642648},{"date":"2024-11-22","current":-1.176095,"twenty":-2.654356,"median":-1.667384,"eighty":-1.249488,"marketCap":55091809},{"date":"2024-11-29","current":-1.171024,"twenty":-2.64274,"median":-1.629813,"eighty":-1.227353,"marketCap":54854273},{"date":"2024-12-06","current":-1.106606,"twenty":-2.639384,"median":-1.600178,"eighty":-1.22448,"marketCap":51836749},{"date":"2024-12-13","current":-1.148018,"twenty":-2.631897,"median":-1.571188,"eighty":-1.222594,"marketCap":53776586},{"date":"2024-12-20","current":-1.167573,"twenty":-2.62396,"median":-1.563013,"eighty":-1.217317,"marketCap":54692620},{"date":"2024-12-27","current":-1.166423,"twenty":-2.616797,"median":-1.547739,"eighty":-1.213926,"marketCap":54638735},{"date":"2025-01-03","current":-1.182527,"twenty":-2.613699,"median":-1.540102,"eighty":-1.211814,"marketCap":55393116},{"date":"2025-01-10","current":-1.304461,"twenty":-2.611376,"median":-1.530098,"eighty":-1.211814,"marketCap":61104858},{"date":"2025-01-17","current":-1.48161,"twenty":-2.609328,"median":-1.528647,"eighty":-1.213041,"marketCap":69403049},{"date":"2025-01-24","current":-1.656458,"twenty":-2.608318,"median":-1.528647,"eighty":-1.213574,"marketCap":77593471},{"date":"2025-01-31","current":-2.167199,"twenty":-2.60789,"median":-1.530098,"eighty":-1.21433,"marketCap":101518124},{"date":"2025-02-07","current":-2.162598,"twenty":-2.593884,"median":-1.54094,"eighty":-1.214734,"marketCap":101302587},{"date":"2025-02-14","current":-1.769189,"twenty":-2.583696,"median":-1.557921,"eighty":-1.214981,"marketCap":82874137},{"date":"2025-02-21","current":-1.863515,"twenty":-2.577932,"median":-1.565558,"eighty":-1.217317,"marketCap":87292655},{"date":"2025-02-28","current":-1.902626,"twenty":-2.570137,"median":-1.584118,"eighty":-1.220574,"marketCap":89124723},{"date":"2025-03-07","current":-1.833607,"twenty":-2.564329,"median":-1.603098,"eighty":-1.220574,"marketCap":85891661},{"date":"2025-03-14","current":-2.672649,"twenty":-2.570137,"median":-1.649192,"eighty":-1.221023,"marketCap":125194918},{"date":"2025-03-21","current":-2.747078,"twenty":-2.60789,"median":-1.669929,"eighty":-1.222594,"marketCap":128681358},{"date":"2025-03-28","current":-2.594838,"twenty":-2.612537,"median":-1.719708,"eighty":-1.224155,"marketCap":121550002},{"date":"2025-04-04","current":-1.679468,"twenty":-2.612537,"median":-1.718575,"eighty":-1.22448,"marketCap":87161019},{"date":"2025-04-11","current":-1.557114,"twenty":-2.610061,"median":-1.684991,"eighty":-1.225254,"marketCap":80811079},{"date":"2025-04-17","current":-1.492618,"twenty":-2.608747,"median":-1.667384,"eighty":-1.226414,"marketCap":77463875},{"date":"2025-04-25","current":-1.557114,"twenty":-2.60789,"median":-1.641927,"eighty":-1.226584,"marketCap":80811079},{"date":"2025-05-02","current":-1.541757,"twenty":-2.60528,"median":-1.62119,"eighty":-1.227308,"marketCap":80014126},{"date":"2025-05-09","current":-1.710675,"twenty":-2.59278,"median":-1.624681,"eighty":-1.230226,"marketCap":88780614},{"date":"2025-05-16","current":-1.653585,"twenty":-2.584263,"median":-1.647756,"eighty":-1.242829,"marketCap":84795847},{"date":"2025-05-23","current":-1.600745,"twenty":-2.580531,"median":-1.656458,"eighty":-1.249451,"marketCap":82086205},{"date":"2025-05-30","current":-2.337537,"twenty":-2.570137,"median":-1.661535,"eighty":-1.249526,"marketCap":119868907},{"date":"2025-06-06","current":-2.328187,"twenty":-2.570137,"median":-1.667973,"eighty":-1.249555,"marketCap":119389431},{"date":"2025-06-13","current":-2.499606,"twenty":-2.555617,"median":-1.681559,"eighty":-1.251898,"marketCap":128179818},{"date":"2025-06-20","current":-2.480906,"twenty":-2.548647,"median":-1.689176,"eighty":-1.252132,"marketCap":127220867},{"date":"2025-06-27","current":-2.462206,"twenty":-2.546034,"median":-1.702427,"eighty":-1.256738,"marketCap":126261915},{"date":"2025-07-03","current":-2.465323,"twenty":-2.537207,"median":-1.714625,"eighty":-1.258423,"marketCap":126421741},{"date":"2025-07-11","current":-2.577524,"twenty":-2.561425,"median":-1.730079,"eighty":-1.259794,"marketCap":132175448},{"date":"2025-07-18","current":-2.898546,"twenty":-2.579766,"median":-1.757979,"eighty":-1.261058,"marketCap":148637445},{"date":"2025-07-25","current":-3.057499,"twenty":-2.600059,"median":-1.764061,"eighty":-1.263206,"marketCap":156788531}],"updateTime":1753620756705}}}